# US 2013/0158037 A1 · Compounds and methods for treating tuberculosis infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158037 A1
- Document ID: US20130158037A1
- Status: Published application
- Kind: A1
- Application number: 13/806,228
- Filed: 2011-06-28
- Published: 2013-06-20
- Earliest claimed: 2010-06-28
- Assignees: Academia Sinica
- Inventors: Chi-Huey Wong; Ying-Ta Wu
- Web page: https://patentgrep.com/patent/US20130158037A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61P 31/04: Antibacterial agents
- C07C 49/753: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 49/755: a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention provides compounds which are potent inhibitors against Lpd activity, PDH activity, and/or the growth of tubercle bacillus, and thus are useful in the treatment of tuberculosis infection and associated conditions. The present invention is further directed to in vitro- and in vzivo-based methods of inhibiting Lpd and/or PDH activity. In certain embodiments, these methods are useful in inhibiting Lpd and/or PDH activity key to a pathogen's survival.

## Claims

### Claim 1

A method of treating a tuberculosis infection, the method comprising administering an effective amount of a compound of Formula (IX):
or a pharmaceutically acceptable salt thereof, to a subject in need thereof;
wherein:
each instance of R20, R21, R22, and R23 is, independently, hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl, halo, nitro, —CN, —ORa, —COORa, —OC(O)Ra, —C(O)Ra, —C(O)NRbRc, or —NRbRc;
each instance of R24a, R24b, R25a, and R25b is, independently, hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl, halo, nitro, —CN, —ORa, —COORa, —OC(O)Ra, —C(O)Ra, —C(O)NRbRc, or —NRbRc; or R24a and R25a are absent, and R24b and R25b together with the carbon atom to which they are attached form an optionally substituted aryl or optionally substituted heteroaryl ring; or R24a and R24b together with the carbon atom to which they are attached form a ═C—Ra group;
each instance of Ra is independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each instance of Rb and Rc is, independently, hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, an amino protecting group, or Rb and Rc, together with the nitrogen atom to which they are bonded are an optionally substituted heterocycloalkyl, an optionally substituted heterocycloalkenyl, or an optionally substituted heteroaryl.

### Claim 2 (depends on 1)

The method of claim 1, wherein each instance of R20, R21, R22, and R23 is hydrogen.

### Claim 3 (depends on 1)

The method of claim 1, R24a and R25a are absent, and R24b and R25b together with the carbon atom to which they are bonded form an optionally substituted aryl or optionally substituted heteroaryl.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim at position 5

5-10. (canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound is of Formula (XI):
or a pharmaceutically acceptable salt thereof;
each instance of R20, R21, R22, and R23 is, independently, hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl, halo, nitro, —CN, —ORa, —COORa, —OC(O)Ra, —C(O)Ra, —C(O)NRbRc, or —NRbRc;
each instance of L1 and L2 is independently or —C(R28)—, wherein R28 is, independently, hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl, halo, nitro, —CN, —ORa, —COORa, —OC(O)Ra, —C(O)Ra, —C(O)NRbRc, or —NRbRc;
X is —O—, —S—, or —N(Rb)—;
each instance of Ra is independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each instance of Rb and Rc is, independently, hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, an amino protecting group, or Rb and Rc, together with the nitrogen atom to which they are bonded are an optionally substituted heterocycloalkyl, an optionally substituted heterocycloalkenyl, or an optionally substituted heteroaryl.

### Claim 12 (depends on 11)

The method of claim 11, wherein each instance of R20, R21R22, and R23 is hydrogen.

### Claim 13 (depends on 11)

The method of claim 11, wherein X is —O—.

### Claim 14 (depends on 11)

The method of claim 11, wherein each instance of L1 and L2 is —N—.

### Claim 15 (depends on 11)

The method of claim 11, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim at position 11

16-30. (canceled)

### Claim 31

A method of treating a tuberculosis infection, the method comprising administering an effective amount of a compound of Formula (III) or (IV):
or a pharmaceutically acceptable salt thereof, to a subject in need thereof;
wherein:
each of R6, R7, and R8, independently, is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl;
each of R9 and R10, independently, is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, halo, nitro, —CN, —ORa, —COORa, —OC(O)Ra, —C(O)Ra, —C(O)NRbRc, or —NRbRc;
each instance of Ra is independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl;
each instance of Rb and Rc is, independently, hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, an amino protecting group, or Rb and Rc, together with the nitrogen atom to which they are bonded are an optionally substituted heterocycloalkyl, an optionally substituted heterocycloalkenyl, or an optionally substituted heteroaryl;
m is 0, 1, or 2; and
n is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9.

### Claim 32 (depends on 31)

The method of claim 31, R7 is hydrogen and R8 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl.

### Claim 33 (depends on 31)

The method of claim 31, wherein R6 is optionally substituted alkyl.

### Claim 34 (depends on 31)

The method of claim 31, wherein each of m and n is 0.

### Claim 35 (depends on 31)

The method of claim 31, wherein m is 1 and R9 is halo.

### Claim 36 (depends on 31)

The method of claim 31, wherein the compound is selected from the group consisting of:
and
pharmaceutically acceptable salts thereof.

### Claim 37 (depends on 31)

The method of claim 31, wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 38

A method of treating a tuberculosis infection, the method comprising administering an effective amount of a compound of Formula (I):
or pharmaceutically acceptable salt thereof, or tautomer thereof, to a subject in need thereof;
wherein:
each instance of R1 and R2, independently, is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, or an amino protecting group; and
R3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, halo, nitro, CN, ORa, COORa, OC(O)Ra, C(O)Ra, C(O)NRbRc, or NRbRc;
each instance of Ra is independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, or optionally substituted heteroaryl; and
each instance of Rb and Rc, is, independently, hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, an amino protecting group, or Rb and Rc, together with the nitrogen atom to which they are bonded are an optionally substituted heterocycloalkyl, an optionally substituted heterocycloalkenyl, or an optionally substituted heteroaryl.

### Claim 39 (depends on 38)

The method of claim 38, wherein R3 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted arylalkenyl, or optionally substituted heteroarylalkenyl.

### Claim 40 (depends on 38)

The method of claim 38, wherein each of R1 and R2, independently, is optionally substituted alkyl.

### Claim 41 (depends on 38)

The method of claim 38, wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim at position 23

42-75. (canceled)
